Difference between revisions of "Vortioxetine-venlafaxine"
From Psychiatrienet
| Line 7: | Line 7: | ||
{{washout8-14}} | {{washout8-14}} | ||
* '''Day 15:''' start with 37,5 mg of venlafaxine. | * '''Day 15:''' start with 37,5 mg of venlafaxine. | ||
| − | {{Day22NoBloodlevelvortioxetine}} | + | {{Day22NoBloodlevelvortioxetine}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref> |
| info = | | info = | ||
* {{theorSS}} | * {{theorSS}} | ||
}} | }} | ||
Revision as of 15:16, 4 November 2015
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from vortioxetine to venlafaxine.[1] [2]
Stop vortioxetine - Day 1: reduce dosage of vortioxetine to 5 mg/day.
- Day 8: stop administration of vortioxetine.
Start venlafaxine- Day 8-14: a wash-out period of 1 week is necessary.
- Day 15: start with 37,5 mg of venlafaxine.
- Day 22: bloodlevel vortioxetine is now zero, so you can increase faster. [3] [4]
More information- Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54
- ↑ KNMP; Informatorium Medicamentorum 2023; Monografie "vortioxetine" (Dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
